Nonetheless, our recent research identified that the occurrence of pyroptosis is more pronounced when PDT at the specific sub organelles, e.g. ER and mitochondria.[10] Very recently, pyroptosis was determined to cause an overabundance of prostaglandin E2 (PGE2), a cyclooxygenase 2 (COX‐2) metabolite, which may foster an immunosuppressive tumor microenvironment (TME), a factor that could impede immunotherapeutic outcomes.[11]. This evidence concerns the gene PTGS2 and neoplasm.